Statement: In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 recieves more than double the dose of cohort 1.
Primary_evidence: INTERVENTION 1:    Arm 1 (Patients With Pain)   Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.   Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days. INTERVENTION 2:    Arm 2 (Patients Without Pain -- Control)   Patient reported pain and symptoms assessment for comparison at baseline.
Secondary_evidence: INTERVENTION 1:    Monotherapy: Alobresib 0.6 mg   Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD. INTERVENTION 2:    Monotherapy: Alobresib 1.4 mg   Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed received alobresib tablets at a dose of 1.4 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD.